cobimetinib

Overview

Allosteric MEK1/2 inhibitor used to target MAPK-pathway-activated tumors.

Evidence in the corpus

• Used as matched targeted therapy for MAP2K1-mutant histiocytosis patients in the Make-an-IMPACT program; MEK inhibitors (trametinib/cobimetinib) contributed to clinical benefit in 17/18 histiocytosis patients receiving matched therapy (mean duration 21.7 months) PMID:36862133.
• Cobimetinib (MEK inhibitor) was among MAPK-pathway directed therapies evaluated across BRAF fusion-positive tumors (N=241, 52 histologies); MEK inhibitor monotherapy provided durable benefit particularly in pilocytic astrocytomas (median 11 months), while combination with BRAF inhibitors was less durable (median 1 month) PMID:38922339.

Resistance mechanisms

• Not reported in corpus.

Cancer types (linked)

• LCH, ECD

Sources

• PMID:36862133
• PMID:38922339

This page was processed by crosslinker on 2026-05-04.